Cargando…

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Izzedine, Hassan, Brocheriou, Isabelle, Mathian, Alexis, Ghez, David, Amoura, Zahir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751673/ https://www.ncbi.nlm.nih.gov/pubmed/36531874 http://dx.doi.org/10.1016/j.ekir.2022.09.004

Ejemplares similares

Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration
por: Izzedine, Hassan, et al.
Publicado: (2020)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

Anticancer Drug-Induced Capillary Leak Syndrome
por: Izzedine, Hassan, et al.
Publicado: (2022)

The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets With Different Outcomes
por: Saïdi, Michèle, et al.
Publicado: (2021)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study
por: Niemann, Carsten U., et al.
Publicado: (2022)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Kidney dysfunction due to AA amyloidosis in a morbidly obese female
por: Izzedine, Hassan, et al.
Publicado: (2023)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Teglgaard, Rebecca, et al.
Publicado: (2023)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Renal toxicities associated with pembrolizumab
por: Izzedine, Hassan, et al.
Publicado: (2018)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
por: Ghia, Paolo, et al.
Publicado: (2022)

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
por: Oyama, Takashi, et al.
Publicado: (2023)

PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease
por: Charlotte, Fréderic, et al.
Publicado: (2022)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
por: Htut, Thura Win, et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

Fatal Algaemia in Patient with Chronic Lymphocytic Leukemia
por: Lanotte, Philippe, et al.
Publicado: (2009)

Subtotal splenectomy for the treatment of chronic lymphocytic leukemia
por: Petroianu, A
Publicado: (2015)

The Coexistence of Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Hangül, Ceren, et al.
Publicado: (2019)

The gut microbiome in patients with chronic lymphocytic leukemia
por: Faitová, Tereza, et al.
Publicado: (2022)

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Membranous nephropathy and carbamazepine
por: Sangeetha, B., et al.
Publicado: (2014)

A rare case of membranous nephropathy associated with chronic inflammatory demyelinating polyradiculoneuropathy
por: Zhang, Qiong, et al.
Publicado: (2023)

A Case of Acute Myeloid Leukemia Concurrent With Untreated Chronic Lymphocytic Leukemia
por: Lee, Hye-Young, et al.
Publicado: (2017)

Functional assessment of p53 in chronic lymphocytic leukemia
por: Le Garff-Tavernier, M, et al.
Publicado: (2011)

APOBEC3 signature mutations in chronic lymphocytic leukemia
por: Rebhandl, S, et al.
Publicado: (2014)

Chronic Lymphocytic Leukemia with Dermatomyositis: A Therapeutic Challenge
por: Kumar, Sudhir, et al.
Publicado: (2020)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4k4gsulju07b42in53drcu79k9